Gene · 4017
Papers2,536
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
601 to 620 of 2,536
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Lysyl Oxidases: Orchestrators of Cellular Behavior and ECM Remodeling and Homeostasis. | Int J Mol Sci | 2022 | 36232685 | PubTator, text mining | PubMed |
| Knock-Out of the Five Lysyl-Oxidase Family Genes Enables Identification of Lysyl-Oxidase Pro-Enzyme Regulated Genes. | Int J Mol Sci | 2022 | 36232621 | PubTator, text mining | PubMed |
| Strategies for Efficient Targeting of Tumor Collagen for Cancer Therapy. | Cancers (Basel) | 2022 | 36230627 | PubTator, text mining | PubMed |
| Qualification of Necroptosis-Related lncRNA to Forecast the Treatment Outcome, Immune Response, and Therapeutic Effect of Kidney Renal Clear Cell Carcinoma. | J Oncol | 2022 | 36226251 | PubTator, text mining | PubMed |
| Translating musculoskeletal bioengineering into tissue regeneration therapies. | Sci Transl Med | 2022 | 36223445 | PubTator, text mining | PubMed |
| Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma. | Front Immunol | 2022 | 36211378 | PubTator, text mining | PubMed |
| LOXL2-dependent deacetylation of aldolase A induces metabolic reprogramming and tumor progression. | Redox Biol | 2022 | 36209516 | PubTator, text mining | PubMed |
| Neuropilin-1 modulates the 3D invasive properties of glioblastoma stem-like cells. | Front Cell Dev Biol | 2022 | 36204684 | PubTator, text mining | PubMed |
| Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression. | Cancer Res | 2022 | 36197797 | PubTator, text mining | PubMed |
| Systematic comparation of the biological and transcriptomic landscapes of human amniotic mesenchymal stem cells under serum-containing and serum-free conditions. | Stem Cell Res Ther | 2022 | 36195964 | PubTator, text mining | PubMed |
A combined analysis of bulk and single-cell sequencing data reveals that depleted extracellular matrix and enhanced immune processes co-contribute to fluorouracil beneficial responses in gastric cancer. | Front Immunol | 2022 | 36189263 | PubTator, text mining | PubMed |
| Identifying the EMT-related signature to stratify prognosis and evaluate the tumor microenvironment in lung adenocarcinoma. | Front Genet | 2022 | 36186418 | PubTator, text mining | PubMed |
| A novel epithelial-mesenchymal transition (EMT)-related gene signature of predictive value for the survival outcomes in lung adenocarcinoma. | Front Oncol | 2022 | 36185284 | PubTator, text mining | PubMed |
| Lysyl oxidase family gene polymorphisms and risk of aneurysmal subarachnoid hemorrhage: a case-control study. | Ann Transl Med | 2022 | 36172092 | PubTator, text mining | PubMed |
| Non-destructive, continuous monitoring of biochemical, mechanical, and structural maturation in engineered tissue. | Sci Rep | 2022 | 36171228 | PubTator, text mining | PubMed |
| Proteomic characterisation of prostate cancer intercellular communication reveals cell type-selective signalling and TMSB4X-dependent fibroblast reprogramming. | Cell Oncol (Dordr) | 2022 | 36169805 | PubTator, text mining | PubMed |
| Inhibition of lysyl oxidase‑like 2 ameliorates folic acid‑induced renal tubulointerstitial fibrosis. | Exp Ther Med | 2022 | 36168418 | PubTator, text mining | PubMed |
| Intratumoral bacteria interact with metabolites and genetic alterations in hepatocellular carcinoma. | Signal Transduct Target Ther | 2022 | 36167691 | PubTator, text mining | PubMed |
| Identification and validation of roles of lysyl oxidases in the predictions of prognosis, chemotherapy and immunotherapy in glioma. | Front Pharmacol | 2022 | 36160460 | PubTator, text mining | PubMed |
| LOXL2 silencing suppresses angiotensin II-induced cardiac hypertrophy through the EMT process and TGF-β1/Smad3/NF-κB pathway. | Iran J Basic Med Sci | 2022 | 36159334 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4017/papers?page=31